Verification of microRNA expression in human endometrial adenocarcinoma by unknown
RESEARCH ARTICLE Open Access
Verification of microRNA expression in
human endometrial adenocarcinoma
Sanja Jurcevic1, Karin Klinga-Levan1, Björn Olsson2 and Katarina Ejeskär1*
Abstract
Background: MicroRNAs are small non-coding RNAs that have been implicated in tumor initiation and progression. In
a previous study we identified 138 miRNAs as differentially expressed in endometrial adenocarcinoma compared to
normal tissues. One of these miRNAs was miRNA-34a, which regulates several genes involved in the Notch pathway,
which is frequently altered in endometrial cancer. The aims of this study were to verify the differential expression of a
subset of miRNAs and to scrutinize the regulatory role of mir-34a on the target genes NOTCH1 and DLL1.
Methods: Twenty-five miRNAs that were previously identified as differentially expressed were subjected to further
analysis using qPCR. To investigate the regulation of NOTCH1 and DLL1 by mir-34a, we designed gain- and loss-of-
function experiments in Ishikawa and HEK293 cell lines by transfection with a synthetic mir-34a mimic and a mir-34a
inhibitor.
Results: Of the 25 validated miRNAs, seven were down-regulated and 18 were up-regulated compared to normal
endometrium, which was fully consistent with our previous findings. In addition, the up-regulation of mir-34a led to a
significant decrease in mRNA levels of NOTCH1 and DLL1, while down-regulation led to a significant increase in mRNA
levels of these two genes.
Conclusions: We verified both up-regulated and down-regulated miRNAs in the tumor samples, indicating various
roles of microRNAs during tumor development. Mir-34a functions as a regulator by decreasing the expression of
NOTCH1 and DLL1. Our study is the first to identify a correlation between mir-34a and its target genes NOTCH1 and
DLL1 in endometrial adenocarcinoma.
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Background
Endometrial cancer (EC) is the most frequently diag-
nosed gynaecological malignancy in the female popula-
tion of the developed countries. According to the World
Cancer Research Fund (WCRF), 320 000 new cases of
endometrial cancer were diagnosed worldwide in 2012
[1]. The most common subtype, endometrioid adenocar-
cinoma (EAC), accounts for approximately 75 % of EC
cases [2]. EAC occurs in pre- and post-menopausal
women and develops from endometrial hyperplasia.
Patients are generally treated with a combination of sur-
gery, chemotherapy and radiotherapy, and in some cases,
hormone therapy is applied [3]. The five-year survival
rate in patients with early stage of the disease is
approximately 80 %, while about 15–20 % develop me-
tastasis [4]. The prognosis is poor for patients with
advanced-stage or recurrent endometrial adenocarcin-
oma due to limited effectiveness of treatment. Under-
standing the pathogenesis of EAC may provide a basis
for development of novel therapeutic strategies.
The discovery of microRNAs (miRNA) has brought
new insights into the pathogenesis of various types of
diseases including cancer. MiRNAs are a class of non-
coding RNA molecules that regulate gene expression
post-transcriptionally, usually through incomplete com-
plementary binding to the 3′–untranslated region (3′-
UTR) of target mRNA, causing transcript degradation or
translation inhibition [5]. So far more than 2500 miR-
NAs have been discovered in human (miRBase v.20),
and the number is still increasing. Since miRNAs may
have multiple target genes, it is estimated they may be
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able to regulate up to 60 % of protein-coding genes,
which make miRNAs one of the most important classes
of regulators in mammals [6]. The relevance of micro-
RNAs in cancer is related to their regulation of essential
cellular processes and pathways, such as cell prolifera-
tion, differentiation and apoptosis. The first association
of miRNAs and cancer was described by Calin and col-
leagues in 2002, who found down-regulation of two
miRNAs, mir-15 and mir-16 in most patients with
chronic lymphocytic leukaemia [7]. Ever since, aberrant
miRNA expression levels have been observed in several
types of tumors like breast [8], endometrial adenocarcin-
oma [9] and other solid tumors [10].
We previously identified 138 dysregulated miRNAs in
endometrial adenocarcinoma, including mir-34a, which
was significantly overexpressed in the cancer samples
with a 5-fold change [11]. MiRNA-34a belongs to the
family miRNA-34, which also includes mir-34b and mir-
34c. Mir-34b and mir-34c are transcribed from a com-
mon miRNA gene located on HSA11, while mir-34a is
located on HSA1. Mir-34a has been shown to have an
aberrant expression in various human tumors [12, 13]
and to regulate several genes involved in the Notch sig-
naling pathway [14].
Abnormal Notch signaling has been reported in sev-
eral cancer types and associated with tumorigenesis [15].
The Notch pathway is one of the basic signaling path-
ways that regulate tissue development and in addition
influences a broad range of events, including prolifera-
tion, differentiation and apoptosis in various cell types
[16, 17]. In mammals, there are four Notch transmem-
brane receptors (NOTCH1-4), and five transmembrane
ligands, which include three Delta-like proteins (DLL1,
DLL2, and DLL4) and two Jagged proteins (JAG1, JAG2).
After activation by ligand binding, the receptor is pro-
teolytically cleaved, which releases an active form of the
Notch intracellular domain (NICD) from the plasma
membrane. The NICD subsequently translocates to the
nucleus and functions as a transcriptional activator to
enhance the expression of target genes [18]. It has been
observed that aberrant activation of the Notch signaling
pathway promotes proliferation in a variety of cancer cell
types, including endometrial adenocarcinoma [19, 20].
Previous studies have proven a direct interaction of
mir-34a to both NOTCH1 [21, 22], and DLL1 [23] using
Luciferase activation assays and western blot.
The purpose of the current study is to validate some
of the miRNAs that we previously demonstrated to be
differentially expressed in EAC [11]. Here we included
the two miRNAs that were the most up-regulated in our
previous study (mir-182 and mir-183) and one of the
downregulated miRNAs (mir-214). Selected were also
miRNAs that belong to families with known association
to several cancer forms. This includes five miRNAs from
the mir-200 family (mir-200a, mir-200b, mir-200c, mir-
429 and mir-141), six from the mir-17-92 cluster (mir-
18a, mir-18a*, mir-92a-1*, mir-17, mir-17* and mir-
20a*), and two from the mir-17 family (mir-106a and
mir-106b*). We also choose to include seven miRNAs
(mir-370, mir-337-5p, mir-376c, mir-377, mir-1247, mir-
758 and mir-300) that are located on the q arm of
chromosome 14, which has been found to be aberrant
and implicated in many types of cancer [24]. Two add-
itional miRNAs (mir-34a and mir-185) that are involved
in many types of cancer [25, 26] were included. We also
investigated the possible involvement of mir-34a in the
development of EAC by using gain- and loss-of-function
experiments to study its regulation of NOTCH1 and
DLL1.
In this study it was revealed that several miRNAs were
dysregulated in EAC and that expression of NOTCH1
and DLL1 mRNA levels were negatively regulated by
mir-34a in the Ishikawa and HEK293 cell lines.
Methods
Tissues and cell lines
A total of 50 archived formalin-fixed, paraffin-
embedded (FFPE) tissue blocks of normal endomet-
rium (20 samples) and endometrial adenocarcinoma
(30 samples) were obtained from the University Hos-
pital of Örebro. The normal endometrial samples
were collected from patients who had undergone hys-
terectomy for nonmalignant conditions. Ten of the
normal endometrial samples were in the proliferative
phase and ten in secretory phase. Patients were
staged according to the International Federation of
Gynecology and Obstetrics (FIGO) classification sys-
tem in 1998, and accordingly 10 tumors were classi-
fied as stage I, 10 as stage II, and 10 as stage III.
Written informed consent for the use of tissues for
research was obtained from patients and healthy do-
nors. The study was reviewed and approved by the
Regional Ethical Committee Uppsala-Örebro (number
2011/123).
The human endometrial cancer cell line Ishikawa, and
the human embryonic kidney 293 (HEK293) cell line were
used to study the possible involvement of mir-34a in
tumorigenesis, by investigating the relationship between
mir-34a and two of its target genes (NOTCH1 and DLL1).
The Ishikawa cell line was cultured in Minimum Essential
Medium Eagle’s (MEM) supplemented with 5 % fetal Bo-
vine serum, L-Glutamine and 1 % Non Essential Amino
Acids. The HEK293 cell line was cultured in Dulbecco’s
modified Eagle medium (DMEM) supplemented with
10 % fetal bovine serum, L-Glutamine, 100 IU/100 μg ml
− 1 penicillin/streptomycin. The cell lines were grown at
37 °C in an atmosphere of 95 % humidity and 5 % CO2.
Jurcevic et al. BMC Cancer  (2016) 16:261 Page 2 of 8
MiRNAs included in the study
We used the Pick-&-Mix microRNA PCR panels for valid-
ation of the selected miRNAs. The panels included
primers for 25 differentially expressed miRNAs (P <
0.001), three endogenous control genes, an interplate cali-
brator and the primer set for detection of a synthetic RNA
spike-in (see Additional file 1). All reactions were run in
triplicates. The panel included mir-182, mir-183, mir-214,
mir-200a, mir-200b, mir-200c, mir-429, mir-141, mir-18a,
mir-18a*, mir-92a-1*, mir-17, mir-17*, mir-20a*, mir-106a,
mir-106b*, mir-370, mir-337-5p, mir-376c, mir-377, mir-
1247, mir-758, mir-300, mir-34a and mir-185.
RNA extraction
Extraction of RNA from FFPE tissues was performed
using a Recover All Total Nucleic Acid Isolation Kit op-
timized for FFPE samples (Ambion, Foster City, CA,
USA) according to the manufacturer’s protocol. Further-
more, total RNA was isolated from the cells using a mir-
Vana miRNA Isolation Kit (Ambion) following the
manufacturer’s protocol. The concentration and purity
of the RNA were measured using the NanoDrop ND-
1000 Spectrophotometer (NanoDrop Technologies,
USA).
Reverse transcription and qPCR for miRNA expression
analysis
Reverse transcription was performed using 2 μl RNA in
10 μl reactions using the miRCURY LNA Universal RT
miR PCR, polyadenylation and cDNA synthesis kit (Exi-
qon, Denmark). For quality control synthetic RNA
spike-in was added to all total RNA samples prior to la-
beling and reverse transcription. The cDNA products
were diluted 100x with RNase-free water and assayed in
10 μl PCR reactions according to the manufacturer’s
protocol; each miRNA assayed by qPCR on the Pick-
&-Mix microRNA PCR panels (Exiqon, Denmark). All
qPCR reactions were performed in triplicates in a Light-
Cycler 480 real-time PCR system (Roche) in 96 well
plates.
Reverse transcription and qPCR for NOTCH1 and DLL1
mRNA expression analysis
Reverse transcription was performed on 200 ng of total
RNA, using the High Capacity RNA-to-cDNA Kit (Ap-
plied Biosystems, USA) according to the manufacturer’s
protocol. Amplification of NOTCH1, DLL1 and the en-
dogenous control GAPDH was performed in 20 μl reac-
tions. Each reaction included 1 μl of 20 TaqMan Gene
Expression Assay (NOTCH1 Hs01062014_m1, DLL1
Hs00194509_m, GAPDH Hs02758991_g, Applied Bio
systems), 10 μl of 2 TaqMan Gene Expression Master
Mix, 4 μl of cDNA (20 ng) and 5 μl water. All qPCR re-
actions were performed in triplicates. The reactions were
run on an Applied Biosystems 7300 Real Time PCR sys-
tem with the following thermal cycles: one cycle of 50 °
C for 2 min; one cycle of 95 °C for 10 min; 40 cycles
with a denaturation step at 95 °C for 15 s and an anneal-
ing/extension step at 60 °C for 60 s. The relative expres-
sion was calculated using the delta Ct method and the
expression of NOTCH1 and DLL1 was normalized to
GAPDH.
Transfection with a synthetic mir-34a mimic and inhibitor
The Ishikawa and HEK293 cell lines were transfected with
mir-34a inhibitor, mir-34 mimic and their respective nega-
tive controls by using the Lipofectamine® RNAiMAX
Transfection Reagent (Life Technologies) in antibiotic-free
Opti-MEM medium (Life Technologies) according to the
manufacturer’s protocol at a final concentration of
100 μM. After 24 h, the medium was changed and total
RNA was collected 48 h after transfection for further ana-
lysis. Transfection efficiency was confirmed with the use
of a commercially available kit (Block-iT Alexa Fluor Red
Fluorescent Oligo; Life Technologies). All transfections
were carried out in duplicates.
Data pre-processing
The qPCR expression data were imported from the
cycler into the GenEx software (MultiD Analyses AB,
Göteborg, Sweden). Initially, raw Ct values were ad-
justed by interplate calibration to compensate for dif-
ferences between runs. An RNA spike-in control
(UniSp6) was used to monitor the efficiency of the
RT reactions. Expression of miRNAs was normalized
using geometric means of the expression of three
stable endogenous control genes, SNORD49A,
SNORD38B and hsa-miR-423-5p, which were shown
in our previous study to be stably expressed in endo-
metrial tissue [11]. Normalization was performed to
the geometric means of the expression of the
endogenous control genes, followed by log2 trans-
formation of the normalized Ct values (see Additional
file 2).
Statistical analysis
All qPCR experiments were carried out in triplicates. Stat-
istical analysis of qPCR data was performed using the
GenEx software. The two-sided Student’s t-test with a
stringent p-value threshold (P < 0.01) was used to deter-
mine differences in miRNA and gene expression between
normal endometrium and endometrial adenocarcinoma.
For comparison, a Mann–Whitney test was also applied
(P < 0.01). Pearson’s correlation coefficient was used to as-
sess the correlation between the expression levels of mir-
34a and its target genes NOTCH1 and DLL1 (P < 0.01).
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Results
Dysregulated miRNA in endometrial adenocarcinoma
versus normal endometrium
In a previous study we quantified the expression levels of
742 miRNAs in 30 cancer and 20 normal endometrium
samples, among these, the commonly down-regulated
miRNA mir-34c showed no significant down-regulation in
the EAC samples, and mir-101 were up-regulated in the
EAC samples compared to normal [11]. A total of 128 miR-
NAs were up-regulated and 10 were down-regulated in
EAC. Hierarchical clustering of the 138 differentially
expressed miRNAs showed a clear distinction between nor-
mal and cancer tissues with only one exception (one cancer
sample clustered among the normal samples). To confirm
the dysregulation of those miRNAs, we here validated the
expression of 25 selected miRNAs using qPCR in the same
tumor and normal samples as in the previous study.
Among the 25 miRNAs that were tested, seven miR-
NAs were down-regulated and 18 miRNAs were up-
regulated compared to normal endometrium (Table 1),
which was fully consistent with previous findings.
MicroRNA-34a, NOTCH1 and DLL1 expression in
endometrial adenocarcinoma
Aberrant expression of mir-34a has been observed in sev-
eral cancers including acute myeloid leukaemia and endo-
metrial adenocarcinoma [11, 27, 28]. To investigate the role
of mir-34a in the development of EAC in the present study
material, the expression level of mir-34a in human endo-
metrial adenocarcinoma and healthy endometrium was in-
vestigated by qPCR. The expression level of mir-34a EAC
samples was higher than in the normal samples, which sug-
gests that mir-34a plays a role in development of EAC.
By qPCR we next examined the expression of NOTCH1
and DLL1 in a subset comprising 12 tumor tissues (4 at
stage I, 4 at stage II and 4 at stage III) and 6 normal sam-
ples, where three were in the proliferative phase and three
in secretory phase. Our results revealed that mRNA ex-
pression of NOTCH1 and DLL1 were significantly lower
(P < 10−08) in the tumors than in normal specimens. The
expression of NOTCH1 and DLL1 in FIGO I-II stages was
significantly lower than in FIGO III stage (P < 0.01). The
relationship between NOTCH1, DLL1 and mir-34a was in-
vestigated using Pearson correlation test, which showed a
negative correlation between mir-34a and NOTCH1 (r =
−0.62, p = 0.0056) and DLL1 (r = −0.69, p = 0.001) for the
sample set as a whole. The correlation prevailed when
tested separately in the tumor and normal groups, al-
though with non-significant p-values in the normal group.
Mir-34a inhibitor enhances and mir-34a mimic suppresses
NOTCH1 and DLL1 mRNA levels
To verify whether mir-34a is a regulator of NOTCH1 and
DLL1 in human endometrial cancer cells, we designed
experiments of gain- and loss-of-function of mir-34a in
the Ishikawa cell line. To further verify also in another cell
type we repeated the experiments in the embryonic kidney
cell line HEK293. A mir-34a inhibitor, a mimic, and the
corresponding negative controls were transfected into
Ishikawa and HEK293 cells and the resulting effects on
the levels of NOTCH1 and DLL1 expression were moni-
tored by qPCR. The relative expression of NOTCH1 and
DLL1 was normalized to GAPDH. Transfection efficiency
was confirmed by using Block-iT Alexa Fluor Red Fluores-
cent Oligo (Figs. 1a, b and 2a, b).
Gene expression of NOTCH1 and DLL1 in the Ishikawa
and HEK293 cell lines was significantly increased in the
mir-34a inhibitor group compared with the control group
(Fig. 1c, d). In addition, the NOTCH1 and DLL1 mRNA
levels were significantly reduced in both cell lines that were
transfected with the mir-34a mimic, compared with those
transfected with the mimic negative control (Fig. 2c, d).
Both findings confirmed that mir-34a is targeting NOTCH1
and DLL1, and thereby influence their mRNA levels.
Table 1 List of 25 miRNAs that were differentially expressed in
endometrial adenocarcinoma compared to normal endometrium
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Discussion
Determination of differences in molecular characteristics
of cancer and normal tissues is helpful for understanding
the complexity in the development of cancer and for de-
veloping effective prognostic and diagnostic tools. In a
previous study we have used qPCR to identify miRNAs
that may contribute to development of endometrial
adenocarcinoma. We investigated the expression of 742
miRNAs, and identified 138 to be differentially
expressed in EAC compared to normal tissues [11].
Most of the dysregulated miRNAs were significantly up-
regulated in EAC, suggesting that miRNAs contribute to
tumor progression primarily by repressing the expres-
sion of tumor suppressor genes.
The miRNA mir-34c is a known tumor suppressor in
other cancer forms, however it is not confirmed in EAC,
Fig. 1 Detection of NOTCH1 and DLL1 expression in transfected Ishikawa and HEK293 cell lines. BLOCK-iT Alexa Fluor red fluorescent and mir-34a
inhibitor transfection in (a) Ishikawa cells and (b) HEK293 cells. The photos were taken 24 h after transfection corresponding to morphology of
cells (left) and BLOCK-iT Alexa Fluor red fluorescent (right). c The level of NOTCH1 and DLL1 expression in Ishikawa cells 48 h after transfection with
mir-34a inhibitor compared with the negative control. d The level of NOTCH1 and DLL1 expression in HEK293 cells 48 h after transfection with
mir-34a inhibitor compared with the negative control
Fig. 2 Detection of NOTCH1 and DLL1 expression in transfected Ishikawa and HEK293 cell lines. BLOCK-iT Alexa Fluor red fluorescent and mir-34a
mimic transfection in (a) Ishikawa cells and (b) HEK293 cells. The photos were taken 24 h after transfection corresponding to morphology of cells
(left) and BLOCK-iT Alexa Fluor red fluorescent (right). c The level of NOTCH1 and DLL1 expression in Ishikawa cells 48 h after transfection with mir-
34a mimic compared with the negative control. d The level of NOTCH1 and DLL1 expression in HEK293 cells 48 h after transfection with mir-34a
mimic compared with the negative control
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mir-34c was shown to be low expressed in endometrial
cancer cell lines [29], however no studies confirm this in
primary tumors, including our material [11]. Even
though mir-101 is down-regulated in many cancer
forms, the up- or down-regulation of mir-101 is not ob-
vious in EAC, both as it is a part of the TrkB-STAT3
regulatory response, where mir-101 gets up-regulated by
increased TrkB levels, and TrkB protein levels is in-
creased in many endometrial carcinoma samples [30].
The stage of the endometrial carcinoma also makes a big
difference on the mir-101 level, since it is up-regulated
in stage 1 compared to normal, however down-regulated
in higher stages compared to normal [31]. In the mater-
ial used in this study we found an up-regulation of mir-
101 (fold change 5,1; p = 1,19e-7) in EAC compared to
healthy tissue [11]. An important limitation of both this
and the previous study [11] was that no tumor adjacent
tissues from the endometrial cancer patients were in-
cluded in the study, thus all differential expressions were
based on the comparison of the miRNA-expression in
endometrium from healthy donors compared to tumors
from EAC patients.
In the present study we validated 25 differentially
expressed miRNAs by qPCR in the same samples as
in the previous study and found that the expression
pattern was consistent with the previous findings. For
example, the expression of mir-182 and mir-183 were
statistically significantly higher in cancer samples
compared to normal endometrium. These two miR-
NAs regulate the tumor-suppressor gene FOXO1,
which is known to be down-regulated in EAC. The
ability of mir-182 and mir-183 to promote FOXO1
repression may play a key role in the development of
EAC by enabling tumors to bypass the cell cycle and
apoptosis [32]. In addition, we observed overexpres-
sion of the mir-200 family, including mir-200a, mir-
200b, mir-200c, mir-141 and mir-429. Gregory and
colleagues reported evidence that suggests an essential
role for the miR-200 family members in regulation of
ZEB1 and ZEB2 genes and in the induction of epithe-
lial to mesenchymal transition (EMT) in several types
of cancer [33]. Moreover, an inhibition of the miR-
200 family using specific anti-miRs resulted in inhib-
ition of cell proliferation in endometrial cancer HEC-
1A and Ishikawa cell lines [34].
Park et al. have investigated the expression pattern of
mir-200c and its role in cell growth in EAC. They report
overexpression of mir-200c in EAC. Moreover, they
showed that mir-200c inhibits expression of the tumor
suppressor gene BRD7. The authors suggested that mir-
200c regulates the translocation of β-catenin from the
cytoplasm to the nucleus via repression of BRD7, result-
ing in up-regulation of its transcriptional target genes,
cyclin D1 and c-myc [35].
In the present study eight miRNAs were down-
regulated in endometrial adenocarcinoma, of which
seven are located in region 14q32. Aberrations in
chromosome 14 have been implicated in many types of
cancer [24] and miRNAs located in 14q32 have been
shown to be under-expressed in gliomas [24], ovarian
cancer [36] and gastrointestinal stromal tumors [37], this
may represent the largest tumor suppressive miRNA
cluster. Our results validate the down-regulation in EAC
of mir-214 [11], which regulates expression of PTEN, a
tumor suppressor gene that produces a protein with
lipid and protein phosphatase function, antagonizing the
PI3K/Akt pathway by dephosphorylation of phosphoino-
sitides. PTEN mutation occurs in approximately 86 % of
EAC cases with microsatellite instability [4]. The muta-
tion of PTEN is well documented in endometrial
hyperplasia, suggesting that it is an early event in
tumorigenesis.
Abnormal expression of mir-185 has been observed in
several types of cancer including prostate [38], breast
[39] and endometrial cancer [11]. One of miR-185 target
genes is AKT1, which is involved in the PI3K/Akt signal-
ing pathway [40], which is often altered in EAC and in-
volved in the development of the disease.
The mir-17-92 family includes the mir-17-92 cluster
and two paralogs, the mir-106a-363 cluster (located on
chromosome X) and the mir-106b-25 cluster (located on
chromosome 7) [41]. Overexpression of the mir-17-92
cluster in a variety of human cancers [42] indicates that
the miRNAs in this cluster may function as oncogenes
and promote cancer development by regulating tumor
suppressor genes and genes that control cell differenti-
ation or apoptosis. In a tumor engraftment model, Dews
and colleagues reported that up-regulation of the cluster
by Myc in colonocytes increases tumorigenesis by pro-
moting angiogenesis through direct repression of TSP-1
and CTGF by miR-18a and miR-19, respectively [43].
Another type of cancer in which mir-17-92 is overex-
pressed is neuroblastoma where it is a poor prognostic
indicator [44]. Due to the high degree of sequence simi-
larity between mir-17-92 and its paralogs (mir-106a-363
and mir-106b-25), it is not surprising that these two
paralogs share the ability to promote tumorigenesis with
miR-17-92. Yu et al., demonstrated that mir-93, which is
a member of the miR-106b-25 cluster, is able to influ-
ence cell proliferation and colony formation of human
colon cancer stem cells [45]. Studies of pancreatic cancer
have shown that mir-106a has an oncogenic role
through promoting cancer cell proliferation and invasion
by targeting TIMP-2 [46].
Several studies have reported down-regulation of mir-
34a in human tumors, such as ovarian cancer, prostate
carcinoma and melanoma [27, 47], and mir-34a has even
been implicated as a potential therapeutic target [25].
Jurcevic et al. BMC Cancer  (2016) 16:261 Page 6 of 8
However recent data show that mir-34a is up-regulated
in head and neck squamous cancer compared to normal
[48], as we find in this study in EAC. Also elevated mir-
34a levels is associated to drug resistance to docetaxel in
breast cancer cells [49]. It has been found that mir-34a
regulates the expression of NOTCH1 [47] and DLL1 [23]
in different types of cancer. Notch is considered an
oncogene in several cancers, such as T-cell acute
lymphoblastic leukemia, as it regulates differentiation
and self-renewal in these tissues, however in other cell
types such as myeloid malignancies it acts as a tumor
suppressor [50]. Thus the cell context is crucial for the
actions of Notch signaling, and consequently likely also
for mir-34a regulation of NOTCH1 expression.
We examined the mRNA level of the NOTCH1 recep-
tor and the DLL1 ligand in 12 tumor and 6 normal tis-
sues, and found a significant decrease in their expression
levels in EAC compared to normal tissues. Additionally,
the expression of NOTCH1 and DLL1 in FIGO stages I-
II was significantly lower than in FIGO III stage (P <
0.01), which suggests that these genes participate in
tumorigenesis. Interestingly, correlation analysis between
mir-34a and clinicopathological features of EAC showed
that mir-34a expression in FIGO I-II stages was signifi-
cantly higher than in FIGO III stage.
To confirm that mir-34a specifically regulates NOTCH1
and DLL1, synthetic mir-34a inhibitor and mimic were
transfected into the Ishikawa and HEK293 cell lines. We
thereby demonstrated that mir-34a regulates NOTCH1
and DLL1 at the mRNA level. As shown in Fig. 2c and d,
transfection of cells with the mir-34a inhibitor resulted in
an increase of the NOTCH1 and DLL1 mRNA levels
compared to their respective negative controls. As ex-
pected, transfection with mir-34a mimic resulted in de-
creased expression of both NOTCH1 and DLL1 mRNA
levels.
Thus, aberrant expression of NOTCH1 and DLL1 in
EAC may be caused by aberrant expression of mir-34a, and
in conclusion mir-34a targets both NOTCH1 and DLL1.
Conclusions
In summary, our study confirms that several miRNAs are
differentially expressed in endometrial adenocarcinoma.
Identification of dysregulated miRNA in EAC can poten-
tially be of great prognostic and diagnostic value and should
be considered when trying to understand the complexity of
the development of endometrial adenocarcinoma.
Furthermore, our study is the first to identify a correl-
ation between mir-34a and its target genes NOTCH1
and DLL1 in endometrial adenocarcinoma. The consist-
ent increase in mir-34a level in EAC, accompanied by a
decrease in NOTCH1 and DLL1 levels, suggests that
mir-34a may serve as a molecular marker of neoplastic
transformation in endometrial adenocarcinoma.
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